<div id="readability-page-1"><p>Precision BioSciences, Inc. (NASDAQ:DTIL - Get Free Report) Director Geno Germano acquired 3,000 shares of Precision BioSciences stock in a transaction that occurred on Tuesday, December 16th. The stock was acquired at an average cost of $4.72 per share, with a total value of $14,160.00. Following the purchase, the director owned 23,883 shares in the company, valued at $112,727.76. The trade was a 14.37% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.</p><div><p><span></span><span>Get <strong>Precision BioSciences</strong> alerts:</span></p></div><h2>Precision BioSciences Stock Performance</h2><p>DTIL traded up $0.11 during midday trading on Wednesday, reaching $4.93. The company's stock had a trading volume of 16,762 shares, compared to its average volume of 270,651. The company has a current ratio of 3.45, a quick ratio of 3.45 and a debt-to-equity ratio of 1.35. The stock has a market cap of $65.37 million, a P/E ratio of -0.59 and a beta of 1.11. The company has a fifty day simple moving average of $5.94 and a 200 day simple moving average of $5.22. Precision BioSciences, Inc. has a twelve month low of $3.61 and a twelve month high of $8.82. </p><p>Precision BioSciences (NASDAQ:DTIL - Get Free Report) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($1.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($1.53). The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $5.40 million. Precision BioSciences had a negative net margin of 11,977.36% and a negative return on equity of 233.77%. During the same period last year, the firm earned ($2.25) EPS.  Research analysts expect that  Precision BioSciences, Inc. will post -1.23 earnings per share for the current year. </p><h2>Analyst Upgrades and Downgrades</h2><p>Separately, Weiss Ratings  reaffirmed a &#34;sell (e+)&#34; rating on shares of Precision BioSciences in a research note on Monday. Two research analysts have rated the stock with a Buy rating and one  has given a Sell rating to the stock. Based on data from MarketBeat, Precision BioSciences  has a consensus rating of &#34;Hold&#34; and a consensus price target of $47.00.</p><p><b>Check Out Our Latest Stock Report on Precision BioSciences</b></p><h2>Institutional Trading of Precision BioSciences</h2><p>Hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC raised its position in  Precision BioSciences by 5.5% during the second quarter. Geode Capital Management LLC now owns 77,712 shares of the company's stock valued at $326,000 after purchasing an additional 4,025 shares in the last quarter.  Bridgeway Capital Management LLC acquired a new stake in  Precision BioSciences during the second quarter worth approximately $260,000.  Corient Private Wealth LLC bought a new position in shares of  Precision BioSciences during the 2nd quarter worth approximately $425,000.  Vanguard Personalized Indexing Management LLC bought a new position in  Precision BioSciences during the third quarter worth $72,000.  Finally, Vanguard Group Inc. increased its position in  Precision BioSciences by 21.5% in the 3rd quarter. Vanguard Group Inc. now owns 492,596 shares of the company's stock valued at $2,719,000 after buying an additional 87,242 shares in the last quarter. Institutional investors and hedge funds own  37.99% of the company's stock. </p><h2>Precision BioSciences Company Profile</h2> (Get Free Report)<p>Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.</p><h2>Read More</h2><ul><li>Five stocks we like better than Precision BioSciences</li><li>How to Know Which Cryptocurrency to Buy: A Guide for Investors</li><li>Massive Breakout in Industrials: 3 Must-Watch Stocks Now</li><li>How to Buy Cheap Stocks Step by Step</li><li>3 Tech Stocks Down Over 60%—Which One Is Worth Buying?</li><li>Why Special Dividends Can be a Delightful Surprise for Income Investors</li><li>25 Years Later, Cisco Finally Recovers From the Dot-Com Crash</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFRJTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFRJTA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Precision BioSciences Right Now?</h2><p>Before you consider Precision BioSciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Precision BioSciences wasn't on the list.</p><p>While Precision BioSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

DTIL

<p>Precision BioSciences Director Geno Germano purchased 3,000 shares at $4.72 each, totaling $14,160, increasing his ownership by 14.37%. The transaction was disclosed to the SEC. The company's stock performance shows a recent trading price of $4.93, with a market cap of $65.37 million. Analysts have mixed ratings on the stock, with a consensus 'Hold' rating and a price target of $47.00. Institutional investors hold 37.99% of the stock.</p>

Precision BioSciences (NASDAQ:DTIL) Director Geno Germano Buys 3,000 Shares